INOVIQ


INOVIQ (ASX:IIQ), formerly BARD1 Life Sciences Ltd (ASX:BD1), is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. INOVIQ has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

Latest Media Releases

INOVIQ - Ovarian Cancer Test Validation

19/04/2024 08:41:00

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85…

INOVIQ and Promega sign Global EXO-NET Agreement

15/04/2024 13:14:00

INOVIQ Ltd (ASX:IIQ) (INOVIQ) and Promega Corporation (Promega) are partnering to unlock the commercial potential of exosomes for research, diagnostic and therapeutic applications. This agreement wi…

Latest News